| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Outcomes of kidney transplantation in HIV-infected recipients.
|
N Engl J Med
|
2010
|
6.26
|
|
2
|
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
|
J Antimicrob Chemother
|
2010
|
2.41
|
|
3
|
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
|
AIDS Res Hum Retroviruses
|
2012
|
1.89
|
|
4
|
A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients.
|
J Am Soc Nephrol
|
2015
|
1.12
|
|
5
|
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.
|
J Pharm Biomed Anal
|
2013
|
1.11
|
|
6
|
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
|
J Acquir Immune Defic Syndr
|
2016
|
1.08
|
|
7
|
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
|
Antimicrob Agents Chemother
|
2015
|
0.99
|
|
8
|
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
|
Lancet HIV
|
2017
|
0.85
|
|
9
|
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
|
Antimicrob Agents Chemother
|
2016
|
0.77
|
|
10
|
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
|
AIDS
|
2017
|
0.75
|
|
11
|
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
|
Lancet
|
2017
|
0.75
|
|
12
|
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
|
Lancet HIV
|
2017
|
0.75
|